Citi initiated coverage of Sarepta (SRPT) with a Sell rating and $7 price target The firm sees “substantial material forward risks” for Sarepta, including the potential withdrawal of Elevidys and possible additional liver-related fatalities with AAVrh74. While the shares are down 89% year-to-date, the stock is still pricing in future Elevidys sales and LGMD2E approval, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Shopify and Unity downgraded: Wall Street’s top analyst calls
- Arrowhead issues statement on exclusive license agreement with Sarepta
- BofA cuts Sarepta to Underperform on uncertain Elevidys future
- Sarepta downgraded to Underperform from Neutral at BofA
- Hold Rating on Sarepta Therapeutics Amid Regulatory Challenges and Uncertain Future for Elevidys